William Paris

The Electrospinning Co. Ltd. develops and manufactures electro spun polymer scaffolds. The firm offers Minetix 3D tissue culture plates. It sell a range of ready-to-use, sterile tissue culture plates containing the Mimetix scaffold for tissue engineering, regenerative medicine and drug discovery research. The company was founded by Robert Stevens and David Mansel Williams in 2010 and is headquartered in Didcot, the United Kingdom.

Kowa Pharmaceutical Europe Co. Ltd. engages in the manufacture of pharmaceutical products. The company was founded in 1947 and is headquartered in Wokingham, the United Kingdom.

Kowa Research Europe Ltd. engages in research and experimental development on social sciences and humanities. The firm develops NK-104, Pitavastatin; K-877, Pemafibrate; K-333, Peretinoin; and K-115, Ripasudil compounds. The company was founded on January 12, 1999 and is headquartered in Wokingham, the United Kingdom.

Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom.

Part of Novartis AG, Sandoz AG is a Swiss company that develops generic medicines and biosimilars. The company is based in Basel, Switzerland.

Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality.

Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom.